New device could make GERD diagnosis quicker and less painful
NCT ID NCT03103789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new, less invasive device that measures the health of the esophagus in people with acid reflux (GERD). Researchers will compare two versions of the device in 75 patients undergoing routine endoscopy. The goal is to see if this technology can diagnose GERD more accurately and comfortably than current methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mucosal impedance testing device
- What this could lead to
- If successful, this could provide a more accurate and less invasive way to diagnose GERD, potentially replacing more uncomfortable tests.
- What could go wrong
- This is an early-stage study with only 75 participants. The new device may not prove more accurate than existing methods, and results may not apply to all GERD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2014
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who are scheduled for endoscopic procedures (esophagogastroduodenoscopy (EGD)) by the principal investigator as part of their routine care and who do not meet any of the pre-defined exclusion criteria will be considered for participation in the study.
- Ages
-
18 to 99 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement Exclusion Criteria: * Age less than 18 years old * Patients unable to give informed consent * Use of acid suppressive therapy within last 10 days * Known history of Barrett's esophagus or gastric surgery, other than non-functioning (slipped) Nissen fundoplication
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastro esophageal reflux are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Vanderbilt University Medical Center Endoscopy Laboratory
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI doctors in training: can a computer learn to diagnose stomach and heart diseases?
- Three quick endoscopic checks may predict who still has reflux after surgery
- Leg raise test may predict acid reflux risk in obese patients before weight-loss surgery
- Pilates may ease acid reflux without pills
- New registry tracks endoscopic Weight-Loss procedures for safety and success
- Healthy volunteers needed to set new standards for reflux testing